Ignite Creation Date:
2024-05-06 @ 8:16 PM
Last Modification Date:
2024-10-26 @ 3:24 PM
Study NCT ID:
NCT06327256
Status:
COMPLETED
Last Update Posted:
2024-04-12
First Post:
2024-03-18
Brief Title:
A Study in Healthy People to Test How Well Different Doses of BI 3000202 Are Tolerated and How They Affect the Way the Body Handles Midazolam
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
Safety Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 3000202 in Healthy Male and Female Subjects Double-blind Randomised Placebo-controlled Parallel Group Design and Evaluation of Midazolam Interaction in Healthy Male and Female Subjects Nested Open Fixed-sequence Intra-individual Comparison
Status:
COMPLETED
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this trial is to investigate the safety tolerability pharmacokinetics PK and pharmacodynamics PD following multiple rising doses of BI 3000202 and to investigate the effect of BI 3000202 on the metabolism of midazolam
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2023-509293-29-00 | REGISTRY | None | None |
| U1111-1299-6907 | REGISTRY | WHO International Clinical Trials Registry Platform ICTRP | None |